Navigation Links
Antibiotic offers potential for anti-cancer activity
Date:1/28/2011

INDIANAPOLIS An antibiotic known for its immunosuppressive functions could also point the way to the development of new anti-cancer agents, researchers at the Indiana University School of Medicine have reported.

The study determined that the compound, tautomycetin, targets an enzyme called SHP2, which plays an important role in cell activities such as proliferation and differentiation. Interestingly, SHP2 mutations are also known to cause several types of leukemia and solid tumors. The findings were reported in the Jan. 28, 2011, issue of the journal Chemistry and Biology.

The potential for developing anti-cancer agents grew out of an attempt to determine how the compound, tautomycetin, exerts its immune suppression activities, said Zhong-Yin Zhang, Ph.D., Robert A. Harris Professor and chairman of the Department of Biochemistry and Molecular Biology.

The finding is also encouraging because SHP2 is a member of a large family of enzymes called protein tyrosine phosphotases (PTPs), which are important in the signaling processes that control all essential cellular functions. Dysregulation of PTP activity has been linked to several human diseases, including cancer, diabetes, and immune dysfunctions. But their makeup has made it difficult to find potential drugs to act on them, characteristics that have labeled the PTPs as "undruggable," Dr. Zhang said.

"So we have identified a lead a natural product produced by the bacteria Streptomyces that should serve as a foundation for the development of therapeutic agents for a large family of protein tyrosine phosphotase targets. Until now these targets, including SHP2 for leukemia and other cancers, have been deemed undruggable," he said.


'/>"/>

Contact: Eric Schoch
eschoch@iupui.edu
317-274-7722
Indiana University School of Medicine
Source:Eurekalert

Page: 1

Related biology news :

1. Common antibiotics and blood pressure medication may result in hospitalization
2. Virginia Tech engineer identifies new concerns for antibiotic resistance, pollution
3. University of Minnesota engineering researcher finds new way to fight antibiotic-resistant bacteria
4. Antibiotics have long-term impacts on gut flora
5. FSU researchers examine how bacteria become resistant to antibiotics
6. Antibiotic appears safe for stroke patients and good companion for tPA
7. Cockroach brains could be rich stores of new antibiotics
8. Insect brains are rich stores of new antibiotics
9. Ancient brew masters tapped antibiotic secrets
10. Ants found to use multiple antibiotics as weed killers
11. Antibiotic may reduce stroke risk and injury in diabetics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2016)... TORONTO , 19 de diciembre de 2016  Mosaic Biomedicals ... el desarrollo acelerado de MSC-1, un anticuerpo humanizado que se espera ... en 2017, con múltiples sitios previstos a lo largo de Europa ... MSC-1 ... factor inhibidor de leucemia (LIF), una citoquina pleiotrópica que se sobreexpresa ...
(Date:12/15/2016)... 15, 2016   WaferGen Bio-systems, Inc. (NASDAQ: ... company, announced today that on December 13, 2016, it ... The Nasdaq Stock Market LLC which acknowledged that, as ... WaferGen,s common stock had been at $1.00 or greater ... compliance with Listing Rule 5550(a)(2) of the Nasdaq Stock ...
(Date:12/12/2016)... 12, 2016  Researchers at Trinity College, Dublin, ... by combining the material with Silly Putty. The mixture ... detector able to sense pulse, blood pressure, respiration, ... The research team,s findings were ... here:  http://science.sciencemag.org/content/354/6317/1257 ...
Breaking Biology News(10 mins):
(Date:1/19/2017)...  ArmaGen, Inc., today announced that it has ... executive officer, as well as a member of ... more than 17 years of executive management experience ... and pharmaceuticals. "Mathias is a ... skillset necessary to lead ArmaGen to its next ...
(Date:1/19/2017)... ... January 19, 2017 , ... DaVita Clinical ... spectrum of drug and device development, and Prism Clinical Research , a ... today announced Verified Clinical Trials (VCT) has been selected by both ...
(Date:1/18/2017)... ... January 18, 2017 , ... ... interconnect using USB or PCI Express, announced the ZEM5310 USB 3.0 FPGA Module, ... into a compact business-card sized form factor suitable for prototyping, testing, and production-ready ...
(Date:1/18/2017)... ... ... Executive search firm Slone Partners proudly supports the SCOPE ... of the clinical trials segment. Hosted in Miami, this conference brings together renowned ... , As executive talent specialists in the industries central to clinical trials, ...
Breaking Biology Technology: